Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?

Pfizer's oncology revenues increased 7% in Q1 2025, driven by drugs like Xtandi and Padcev, with the 2023 acquisition of Seagen further bolstering its ADC portfolio. The company's 2025 EPS estimate has risen to $3.06, and its forward P/E ratio of 7.77 is below the industry average, suggesting an attractive valuation relative to peers like AstraZeneca, Merck and Bristol-Myers, despite PFE's stock declining 6.8% YTD.

Analysis

Pfizer's oncology division demonstrates robust growth, with revenues increasing 7% operationally in Q1 2025, primarily driven by key products such as Xtandi, Lorbrena, Padcev, and the Braftovi-Mektovi combination. The strategic acquisition of Seagen in 2023 has significantly enhanced Pfizer's oncology portfolio, adding four approved antibody-drug conjugates (ADCs) – Adcetris, Padcev, Tukysa, and Tivdak – which made meaningful revenue contributions in 2024 and Q1 2025, and also brought next-generation ADC candidates into the pipeline. Further strengthening its future prospects, Pfizer markets six oncology biosimilars, has advanced several candidates like sasanlimab, vepdegestrant, and sigvotatug vedotin into late-stage development, and recently secured an exclusive licensing deal with China's 3SBio for a dual PD-1 and VEGF inhibitor. Despite these positive operational developments and a promising oncology pipeline, Pfizer's stock has underperformed, declining 6.8% year-to-date against a 0.2% rise for the industry. However, the company's valuation appears attractive, with a forward P/E ratio of 7.77, significantly below the industry average of 15.05 and its own 5-year mean of 10.90. This is complemented by upward revisions in earnings estimates, with the Zacks Consensus Estimate for 2025 EPS rising from $2.98 to $3.06 and for 2026 EPS from $3.00 to $3.09 over the past 60 days. The competitive landscape remains intense, with AstraZeneca's oncology sales growing 13% in Q1 2025, and major drugs like Merck's Keytruda and Bristol-Myers' Opdivo holding significant market shares.

Key Decisions for Investors

• Investors should consider Pfizer's compelling valuation, evidenced by its low forward P/E ratio relative to the industry and its historical average, in light of the strong growth in its oncology segment and positive EPS estimate revisions.
• Monitor the continued revenue contribution from Seagen's acquired assets and the clinical progression of Pfizer's late-stage oncology pipeline, as these are key catalysts for future growth and potential stock re-rating.
• Evaluate the year-to-date stock underperformance against the company's fundamental strengths in oncology, but remain cognizant of the highly competitive environment dominated by established players like AstraZeneca, Merck, and Bristol-Myers.